Upcoming changes in the coverage of medical procedures in Switzerland

28

Dec 2020

On December 22, 2020, the Swiss Federal Office of Public Health announced the changes that will occur to the Services Ordinance (KLV/OPre). The updates will enter into force on January 1, 2021 (unless specified otherwise), and they include:

  • Mostly wording changes will occur in the general part of the Services Ordinance (KLV/OPre)
  • Various changes in coverage of explicitly evaluated services, such as different reimbursement conditions, the extension of reimbursement of certain services, and new reimbursement decisions will occur in Annex 1 of the Services Ordinance (explicitly evaluated services). The most important examples are:
    • Service “Metabolic surgery” was introduced instead of “Surgical therapy of obesity”. This service is covered with evidence development until the end of 2025. Reimbursement is provided in certain conditions, only
    • Coverage of evidence development of “Autologous Chondrocyte Transplant” is extended until the end of 2024
    • Coverage of evidence development of ultrasound focused therapy of pallidum, thalamus and subthalamus, for the treatment of severe chronic neuropathic pain refractory to therapy is extended until the end of 2025
    • Various other changes in conditions for reimbursement of other services
    • Removal of various services from Annex 1  
  • Mostly wording updates will occur in Annex 1a of the Services Ordinance (ambulatory-before-stationary services)
  • Various updates regarding reimbursement of medical aids will occur in Annex 2 of the Services Ordinance (List of Medical Aids and Equipment). The changes will enter into force at different times - January 1, 2021; April 1, 2021; July 1, 2021; and January 1, 2022
  • Changes in Annex 3 of the Services Ordinance (List of Analyses). The changes will enter into force on the first of February 2021.
    • The most important change is the inclusion of one new test (Mycobacterium tuberculosis complex, rifampicin resistant bacteria, antibiogram, with the code 3488.00 and tariff of CHF 47) will be reimbursed since January 1, 2021
    • Several wording updates will also occur
  • Changes in Annex 4 of the Services Ordinance (List of Medications with Tariff)

See more details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more